Cipla to Acquire Paediatric-focused Inzpera Healthsciences for ₹1.11 billion

Cipla Ltd. on Monday said it has signed a definitive agreement to acquire a 100% stake in Inzpera Healthsciences Ltd. for ₹1.11 billion in cash. Inzpera specialises in differentiated paediatric pharmaceutical and wellness products, the company said in an exchange filing.

The enterprise value of Inzpera is pegged at ₹1.20 billion, with the final consideration adjusted for working capital. The deal includes equity shares and certain non-convertible redeemable preference shares.

In 2024–2025 Inzpera reported revenue of ₹267.5 million. Cipla said the acquisition will combine Inzpera’s paediatric portfolio with its own extensive distribution and operational network to enhance growth and scalability.

The transaction is expected to close within a month from signing, after which Inzpera will become a wholly owned subsidiary of Cipla.